Medidata to Offer DCT Platform


Medidata, a Dassault Systèmes company, has announced the launch of the Medidata Decentralized Clinical Trials (DCT) Program, a comprehensive set of unified, secure technologies that enable full decentralization across the clinical trial continuum. Drug, vaccine, and medical device developers (sponsors) and contract research organizations (CROs) can take advantage of the platform offering on the market which combines:

  • Technology and workflows to virtualize patient participation
  • Tools that facilitate sponsor oversight of patient safety and data quality
  • Direct-to-patient services, including facilitation of delivery of study drugs to the home

To date, Medidata has applied its decentralizing technologies across more than 44,000 clinical sites around the world in multiple languages involving more than 600,000 patients with a wide array of illnesses.

For more information, click here.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.